Story detail view · 2026-07
STAT+: Eli Lilly to acquire psychedelics-focused biotech AtaiBeckley

STAT+: Eli Lilly to acquire psychedelics-focused biotech AtaiBeckley

Quick Summary

Eli Lilly is buying the psychedelics-focused biotech AtaiBeckley for $2.8 billion upfront, a move that will expand its neuroscience pipeline.

Continue Reading on STAT News

Get instant updates on Telegram

Join our channel to receive the latest headlines and breaking stories as soon as they are published.

Join channel

Comments (0)

Join the conversation. Comments are rate-limited, secured, and GDPR-compliant.

No comments yet. Be the first to share your thoughts!

Write a comment

0 / 500